Enriched Expression of Neutral Sphingomyelinase 2 in the Striatum is Essential for Regulation of Lipid Raft Content and Motor Coordination

Laura Hui-Ru Tan 1 · Angela Jin-Rong Tan 1 · Yu-Ying Ng 1 · John Jia-En Chua 2,3,4 · Wee-Siong Chew 5 · Sneha Muralidharan 6 · Federico Torta 7 · Bamaprasad Dutta 8 · Siu Kwan Sze 8 · Deron R. Herr 5 · Wei-Yi Ong 1,2

Received: 25 April 2017 / Accepted: 20 September 2017 / Published online: 17 October 2017
© The Author(s) 2017. This article is an open access publication

Abstract Sphingomyelinases are a family of enzymes that hydrolyze sphingomyelin to generate phosphocholine and ceramide. The brain distribution and function of neutral sphingomyelinase 2 (nSMase2) were elucidated in this study. nSMase2 mRNA expression was greatest in the striatum, followed by the prefrontal cortex, hippocampus, cerebellum, thalamus, brainstem, and olfactory bulb. The striatum had the highest level of nSMase2 protein expression, followed by the prefrontal cortex, thalamus, hippocampus, brainstem, and cerebellum. Dense immunolabeling was observed in the striatum, including the caudate-putamen, while moderately dense staining was found in the olfactory bulb and cerebral neocortex. Electron microscopy of the caudate-putamen showed nSMase2 immunoreaction product was present in small diameter dendrites or dendritic spines, that formed asymmetrical synapses with unlabeled axon terminals containing small round vesicles; and characteristics of glutamatergic axons. Lipidomic analysis of the striatum showed increase in long chain sphingomyelins, SM36:1 and SM38:1 after inhibition of nSMase activity. Quantitative proteomic analysis of striatal lipid raft fraction showed many proteins were downregulated by more than 2-fold after inhibition or antisense knockdown of nSMase; consistent with the notion that nSMase2 activity is important for aggregation or clustering of proteins in lipid rafts. Inhibition or antisense knockdown of nSMase2 in the caudate-putamen resulted in motor deficits in the rotarod and narrow beam tests; as well as decreased acoustic startle and improved prepulse inhibition of the startle reflex. Together, results indicate an important function of nSMase2 in the striatum.

Keywords nSMase2 · Motor function · Startle reflex · Lipid rafts · GW4869 · Antisense knockdown · Membrane lipids · Microdomains · Lipidomics · Proteomics · Sphingolipids

Laura Hui-Ru Tan and Angela Jin-Rong Tan have equal contribution.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12035-017-0784-z) contains supplementary material, which is available to authorized users.
Abbreviations

Aβ amyloid beta
AD Alzheimer’s disease
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
DAPI 4′,6-diamidino-2-phenylindole
LC-MS/MS liquid chromatography-mass spectrometry/mass spectrometry
NMDA N-methyl-D-aspartate
nSMase2 neutral sphingomyelinase 2
PD Parkinson’s disease
PMA phorbol 12-myristate 13-acetate
PVDF polyvinylidene difluoride
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
siRNA small interfering RNA
TBS-Tween Tris-buffered saline—Tween
TFN-α tumor necrosis factor-alpha
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling

Introduction

Sphingomyelinases (SMases) belong to a class of enzymes that hydrolyze sphingomyelin to generate phosphocholine and ceramide. They play key roles in sphingomyelin breakdown that results in altered neural membrane compositions and the generation of ceramide, a well-established modulator of various important cellular signaling pathways regulating cell differentiation, proliferation, cell survival, and cell death [1–3]. They are categorized according to their pH level at which their activity is optimal and include lysosomal acid sphingomyelinase (A-SMase), secreted zinc-dependent acid sphingomyelinase (S-SMase), magnesium-dependent neutral sphingomyelinase (nSMase), magnesium-independent neutral sphingomyelinase, and alkaline sphingomyelinase. Of these, A-SMase and nSMase are thought to be the major players in stress-induced ceramide production [4, 5]. Four neutral SMases have been identified, namely, nSMase1, nSMase2, nSMase3, and MA-nSMase (mitochondrial-associated nSMase). They require a neutral pH and divalent cations such as Mg2+ or Mn2+ to specifically hydrolyze the phosphocholine-headgroup from sphingomyelin [6, 7]. With the exception of nSMase3, nSMases possess a DNase I-type catalytic core, suggesting a common mechanism for sphingomyelin catalysis [4].

A comparison of the three nSMase isoforms is presented in Table 1 [8–16]. nSMase2 is a 655 amino acid protein with a molecular weight of 71 kDa. It appears to be the most prominent and well-researched isoform. nSMase2 is localized at the Golgi apparatus and plasma membranes in certain cell lines [17, 18]. Various factors such as TNF-α, PMA [19], and H2O2 [4] trigger nSMase2 to translocate from the Golgi apparatus to the plasma membrane. nSMase2 is involved in the modulation of dendritic spine size [20], hippocampal neurite outgrowth, and synaptogenesis [21]. Pharmacological inhibition or genetic mutation of nSMase2 prevented TNFα-induced generation of ceramide, phosphorylation of NR1 subunits, clustering of NR1, enhancement of N-methyl-D-aspartate (NMDA)-evoked calcium flux and excitatory post-synaptic currents in cultured hippocampal neurons [22]. nSMase2 inhibition also increased PSD-95, increased the number of AMPA receptors, and impaired spatial and episodic-like memory in mice [23]. Inhibition of nSMase2 via treatment with nSMase2 siRNA or nSMase inhibitor GW4869 decreases ceramide production and reduces dopamine reuptake in PC12 cells, while addition of C6 ceramide increases dopamine uptake [24]. nSMase2 may also have a role in Alzheimer’s disease. It is activated by Aβ and leads to accumulation of ceramide in neurons, oligodendrocytes and cerebral endothelial cells, and apoptosis [25–27].

Although much attention has been placed on the functional and physiological roles of SMases in vitro, relatively little is known about the normal expression and function of nSMase2 in the brain. Previous studies have shown high level of nSMase2 activity in the parietal cortex and corpus striatum of the rat brain [28]. In this study, we identified the striatum as the brain region that has among the highest expression of nSMase2, and carried out intrastriatal inhibition of nSMase2 to establish its effect on lipid and protein profiles and behavior. Results demonstrate an important role of nSMase2 in motor function and sensorimotor gating.

Materials and Methods

Chemicals

The nSMase inhibitor GW4869 was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, USA) and was diluted in vehicle (saline). Antisense and scrambled sense nSMase2 oligonucleotides were purchased from Exiqon (Exiqon A/S, Denmark) of 20 nmol concentration. The sequences were 5′ GTAGAAAAATACGTGACT 3′ for the antisense and 5′ TGATAGAAAATCCTGGCA 3′ for scrambled sense oligonucleotide. Both antisense and scrambled sense oligonucleotides were reconstituted in 10 μl of nuclease-free water.

Animals

Adult male Wistar rats (250–300 g) were procured from InVivos Singapore and housed in temperature-controlled (23 ± 1 °C), individually ventilated cages on a 12-h light/12-h dark cycle (7 a.m.–7 p.m.) with access to food and water.
Rats were acclimatized for 4 days prior to the start of experiments. All procedures were in accordance with the Principles of Laboratory Animal Care and approved by the Institutional Animal Care and Use Committee of the National University of Singapore.

Stereotaxic Injections

Anesthesia was induced and maintained in rats using the inhalational anesthetic isoflurane (Sigma-Aldrich, St Louis, USA). These were then mounted on a stereotaxic frame (Stoelting, Wood Dale, USA) and the bregma exposed via a midline incision on the scalp. Small craniotomies were performed over the injection sites: 1.0 mm anterior and 3.0 mm lateral to the bregma on both sides, and 5.0 mm from the surface of the cortex. These coordinates correspond to the caudate-putamen of the striatum which was determined using the rat brain atlas of Paxinos and Watson [29]. GW4869 or saline, or antisense or scrambled sense oligonucleotides were injected into the striatum bilaterally. The volume injected at each site was 2 μl and the injection rate was 4 min per injection.

Table 2  Acoustic startle reflex. Summary of different trials. The session consisted of 32 discrete trials, which were conducted in pseudorandom order. The prepulse-to-pulse interval was set at 100 ms.

| Trial          | Number of trials | Intensities (dB) | Duration       |
|----------------|------------------|------------------|----------------|
| Acclimation/    | –                | 65               | 5 min          |
| no stimulus    |                  |                  |                |
| Pulse          | 17               | 120              | 40 ms          |
| Prepulse + pulse| 5                | 69 + 120         | 20 ms + 40 ms  |
|                | 5                | 73 + 120         |                |
|                | 5                | 77 + 120         |                |

Real-Time Reverse Transcriptase Polymerase Chain Reaction

Six adult male Wistar rats were used for this part of the study. They were deeply anesthetized with intraperitoneal injection of ketamine and xylazine cocktail (prepared with 7.5 ml ketamine (75 mg/kg), 5 ml xylazine (10 mg/kg), and 7.5 ml 0.9% sodium chloride solution) and decapitated. The olfactory bulb, prefrontal cortex, striatum, thalamus, cortex 1 (which includes the primary and secondary motor cortex and primary somatosensory cortex), cortex 2 (which includes the parietal association cortex and secondary auditory cortex), hippocampus, cerebellum, and brainstem were quickly dissected, immersed in RNAlater® solution (Ambion, TX, USA), and snap frozen in liquid nitrogen. TRizol reagent (Invitrogen, CA, USA) was used to extract total RNA, according to the manufacturer’s protocol. Purification of RNA was performed using RNeasy® Mini Kit (Qiagen, Inc., CA, USA). Reverse transcription was done using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA). The reaction conditions were as follows: 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 s. Real-time PCR amplification was performed using 7500 Real-Time PCR system (Applied Biosystems, CA, USA), TaqMan® Universal PCR Master Mix (Applied Biosystems, CA, USA), and TaqMan® Gene Expression Assay Probes for A-SMase, nSMase1, nSMase2, nSMase3, and β-actin (Applied Biosystems, CA, USA) according to the manufacturer’s instructions. The PCR conditions were as follows: incubation at 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All reactions were performed in triplicates. The threshold cycle (CT) was determined based on the number of cycles in which the reporter fluorescence emission exceeded the preset threshold level. Amplified transcripts were calculated using the comparative CT method against the standard curve and the formula for relative fold change = 2 ^ −ΔΔCT [30]. Relative quantification of each of the nSMase isoforms was performed using a standard curve for each target.
Western Blot Analysis

Four adult Wistar rats were used for this part of the study. They were anesthetized deeply and sacrificed by decapitation. Different parts of the rat brain such as the olfactory bulb, prefrontal cortex, striatum, thalamus, cortex 1, cortex 2, hippocampus, cerebellum, and brain stem were dissected and homogenized using a Tissue Tearor™ (Biospec, OK, USA) in T-Per® Tissue Protein Extraction Solution containing 1% Hal™ protease inhibitor and 1% EDTA solution (Thermo Fisher Scientific, IL, USA). The homogenates were centrifuged at 12,000g, and the protein concentration in the supernatant was calculated using the Bio-Rad protein assay kit (Bio-Rad Laboratories, CA, USA). Total proteins were resolved in 15% SDS polyacrylamide gels under reducing conditions and electrotransferred to polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia Biotech, Little Chalfont, UK). This was incubated with 5% skim milk in 0.1% TBS-Tween for 1 h to block non-specific binding sites. The PVDF membrane was then incubated overnight with a rabbit polyclonal antibody to nSMase2, diluted 1:1600 dilution in 5% skim milk in 0.1% TBS-Tween at 4 °C. The antibody was raised against a region within amino acids 461 and 655 at the C-terminus of nSMase2 of human origin (Santa Cruz Biotechnology, Santa Cruz, USA). The membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG (ThermoFisher Scientific, MA, USA) for 1 h at room temperature. Labeled protein was visualized with an enhanced chemiluminescence kit according to the manufacturer’s instructions (Pierce, Rockford, IL, USA). Intensities of the bands were quantified using densitometric analyses. Western blots were also used to verify knockdown of nSMase2 protein by antisense oligonucleotide. Rats used in the rotarod and balance beam tests were anesthetized deeply and sacrificed by decapitation. The striatum was dissected from these rats and analyzed by Western blots to check knockdown efficiency.

Immunohistochemistry

Six adult Wistar rats were used for this portion of the study. They were anesthetized deeply and perfused through the left cardiac ventricle with a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed and sectioned coronally at 100 μm using a vibratome. Sections were washed for 3 h with phosphate-buffered saline (PBS) and incubated overnight at 4 °C with an affinity-purified rabbit polyclonal antibody to nSMase2 (Santa Cruz Biotechnology, Santa Cruz, USA), diluted 1:200 in PBS. They were then incubated for 1 h in a 1:200 dilution of biotinylated horse anti-rabbit IgG (Vector, Burlingame, CA, USA), reacted for 1 h with avidin-biotinylated horseradish peroxidase complex, and treated for 5 min in 0.05% 3, 3-diaminobenzidine tetrahydrochloride solution in Tris buffer containing 0.05% hydrogen peroxide. Some of the sections were mounted on glass slides, counterstained with methyl green, and coverslipped, while the remaining sections were processed for electron microscopy.

Electron Microscopy

Immunostained sections of the striatum were subdissected into smaller portions and stained with 1% osmium tetroxide for 1 h. They were dehydrated in an ascending series of 25, 50, 75, and 100% ethanol and acetone, and embedded in Araldite. Thin sections were obtained from the first 5 μm of the immunostained sections, mounted on Formvar-coated copper grids, and stained with lead citrate. They were viewed using a JEOL 1010EX electron microscope (JEOL, Japan).

Lipidomic Analysis

Rats that have completed the rotarod and balance beam tests (see below) were used for this part of the study, with six rats in each group that received GW4869 or saline injection to the caudate-putamen. These were deeply anesthetized and sacrificed by decapitation, and the striatum dissected out and snap frozen in liquid nitrogen. The tissue was thawed, and weighed, and lipids were extracted and analyzed for lipidomics as previously described [31]. Briefly, the tissue was transferred to Omni tubes containing 50 mg of 1.4-mm ceramic beads. One milliliter of BUME (butanol: methanol 1:1) mixture containing 1.07 nmol/ml of 12:0 SM (860583, Avanti Polar Lipids, USA) and 0.18 nmol/ml of C17 ceramide (860517, Avanti Polar Lipids, USA) standards was added to around 30 mg of wet tissue that was then homogenized for few seconds using an Omni bead mill homogenizer. The homogenized tissue was sonicated for 30 min and centrifuged at 14,000g to precipitate the protein phase. The supernatant, containing the extracted lipids, was analyzed by positive mode electrospray ionization (ESI) mass spectrometry (MS) using an Agilent 6495 QQQ mass spectrometer. Lipid separations were performed on a UHPLC Agilent 1290, using a reversed phase Agilent ZORBAX RRHD Eclipse Plus C18 column (95 Å, 2.1 × 100 mm, 1.8 μm) at 40 °C. Mobile phases A (40% acetonitrile in 60% water with 10 mM ammonium formate) and B (10% acetonitrile in 90% isopropanol with 10 mM ammonium formate) were mixed according to the following gradient: 20% B at 0 min, to 60% B at 2.0 min, to 100% B at 7.0 min, maintained at 100% B from 7.0 to 9.0 min, re equilibrated at 20%B from 9.01 min to 10.80 min. Lipids were measured using a dynamic MRM method. Possible significant differences were analyzed using Student's t test. P < 0.05 was considered significant.
Proteomic Analysis of Lipid Rafts

Rats that have completed the rotarod and balance beam tests were used for this part of the study, with six rats in each group that received GW4869 or saline; or antisense or scrambled sense oligonucleotide injection to the caudate-putamen. To determine if nSMase2 was involved in the proteome of lipid rafts, a label-free quantitative proteomics approach was carried out using LC-MS/MS analysis and Protein Abundance Index (emPAI) protocol. Rats were anesthetized deeply and sacrificed by decapitation. The striatum was dissected out, and in view of the small amount of tissue, lipid rafts were isolated using the UltraRIPA kit according to the manufacturer’s instructions (BioDynamics Laboratory, Japan). This is a novel but validated small-scale platform to rapidly extract membrane proteins or membrane-associated proteins enriched in lipid rafts with a native structure and function [32]. In brief, rat striatal samples were first homogenized in conventional RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% deoxycholate) using a Tissue Tearor™ (Biospec, OK, USA). After purification of the RIPA-insoluble fraction, lipid raft proteins were extracted using another B-buffer which solubilizes the RIPA-insoluble lipid raft proteins (BioDynamics Laboratory, Japan). Lipid raft fractions from the four groups were resolved by 12.5% SDS-PAGE and stained with Coomassie brilliant blue. Each sample lane was cut separately and sliced into small pieces for destaining, washing, reduction, alkylation, and trypsin digestion using sequencing-grade modified trypsin (Promega, Madison, WI), at 37 °C overnight. Tryptic peptides were extracted with 5% acetic acid/50% ACN buffer and vacuum dried. They were reconstituted in 0.1% formic acid (FA) solution before LC-MS/MS analysis using an online Dionex UltiMate 3000 UHPLC system coupled with a Q Exactive mass spectrometer (Thermo Scientific Inc., Bremen, Germany). Each sample was injected into the LC-MS/MS for three times. The acquired raw data were converted into the mascot generic format (mgf) files using Proteome Discoverer 1.4.1.14 software (Thermo Fisher, MA) with MS2 spectrum processor for deisotoping. All the searches were performed using the in-house mascot search engine (Mascot, version 2.4.1: Matrix Science, London, UK) using UniProt Knowledgebase (UniProtKB) rat database (31,555 sequences, 17,339,165 residues) along with the reverse sequences. Carbamidomethyl at cysteine was set as a static modification and methionine oxidation, and asparagines and glutamine deamidation as dynamic modifications. Full trypsin digestion with maximum 2 missed and/ or non-specific cleavages set as digestion parameter; while no. 13C of 2, 10 ppm precursor mass, and 0.02-Da fragment mass tolerance were set as other search parameters. Target-decoy search strategy with cutoff set to ≤ 1% false density rate (FDR) and proteins identified with > 2 unique peptides were used for further analysis. The emPAI value for each identified protein was calculated by Mascot during search and was used for the label-free quantification.

Rotarod Test

Six adult male Wistar rats in each group, i.e., GW4869, saline, antisense-, or scrambled sense oligonucleotides, were used in this portion of the study. Rats underwent intrastriatal injection of GW4869 or saline 6 h before undergoing the rotarod test. The latter was carried out 6-h post injection, since the inhibitory effect of GW4869 was shown to be significantly reduced by 24 h [12]. For the oligonucleotide-injected groups, rats underwent intrastriatal injection of antisense or scrambled sense oligonucleotides before undergoing rotarod testing for 5 days. They were positioned on an accelerating rotarod cylinder and were timed based on how long they remained on the rotarod. The speed gradually increased from 4 to 40 rpm within a span of 5 min. A trial was considered to have ended when a rat fell off the rotarod cylinder or gripped the cylinder and spun for 2 successive revolutions without trying to walk on the rungs. The duration (in seconds) on the device was recorded. Rotarod test data were presented as average latency to fall (3 trials) from the rotarod. Possible significant differences were analyzed using Student’s t test. P < 0.05 was considered significant.

Beam Crossing Test

The time to cross the center 80 cm of a 1-m round beam of 2.5-cm diameter was recorded. The beam was elevated 90 cm over the ground and had to be crossed three times. Rats were

![Image](https://example.com/image.jpg)
positioned at one end of the beam with the animal’s home cage, bedding material, and food pellets at the opposite end. Rats were trained 2 days prior to the day of testing. During the training period, rats were encouraged to cross the beam by gentle nudging. Training trials were performed repeatedly until each animal successfully traversed the beam three times without pausing or turning around. On the day of testing, a baseline recording of three trials per rat was performed before intrastriatal injection of GW4869 or saline. Six hours after injection, rats were made to cross the beam for three trials. Trials where the rat spent more than 60 s to cross or fell from the beam were recorded as 60 s. Trials where the rat paused or turned around were repeated. The average of the trials was recorded. The same testing procedure was performed for 5 days after intrastriatal injection of antisense or scrambled sense oligonucleotide. Possible significant differences were analyzed using Student’s t test. P < 0.05 was considered significant.

**Acoustic Startle Reflex Test**

Startle reflex testing was conducted 6 h after surgery, using a startle chamber that contained a transparent Plexiglas tube mounted on a Plexiglas frame (SR-LAB, San Diego Instruments, San Diego, CA, USA). A high-frequency loudspeaker located in the chamber emits an uninterrupted background noise of 65 dB and the various acoustic stimuli. Vibrations from the Plexiglas cylinder as a result of the whole body startle response of the rats were transduced into analog signals (0–10,000-mV range) recorded by the load cell platform. The signals were digitized and analyzed using SR-LAB Startle Response Software (San Diego Instruments, San Diego, CA, USA). The protocol for measuring prepulse inhibition is based on a previous study [33]. The startle session proceeded after a 5-min acclimatization period in the tube with a background noise level of 65 dB that was sustained for the entire startle session. Animals were then exposed to a succession of 32 discrete trials comprising of 17 40-ms presentations of a 120-dB pulse (pulse-alone), five 20-ms presentations of each prepulse intensity (69, 73, 77 dB) 100 ms prior to a 40-ms presentation of a 120-dB pulse (prepulse + pulse). No-stimulus trials, whereby no acoustic pulse was delivered, were also recorded to evaluate general

**Fig. 2** a Immunoblot of the striatum of adult rats injected with scrambled sense nSMase2 (SS) and antisense nSMase2 (AS). Antisense knockdown of nSMase2 resulted in reduced density of the 71-kDa band, indicating effectiveness of the knockdown, as well as specificity of the antibody. b Densitometric analysis of nSMase2 band intensities of SS- and AS-injected rats, normalized to β-actin. Data represents the mean and standard error from n = 6 Wistar rats in each group. Each bar in the diagram indicates mean + SEM

**Fig. 3** a Immunoblot of adult rats in selected parts of the rat brain including the prefrontal cortex (PFC), striatum (STR), thalamus (THA), hippocampus (HPC), cerebellum (CB), and brainstem (BS). The striatum was found to have the highest nSMase2 protein expression, followed by the prefrontal cortex, thalamus, hippocampus, brainstem, and cerebellum. b Densitometric analysis of nSMase2 band intensities, normalized to β-actin. Data represents the mean and standard error from n = 4 Wistar rats. Each bar in the diagram indicates mean + SEM
motor activity of the animals. The pulse and prepulse stimuli used were in the form of a sudden elevation in broadband white noise level from background (65 dB), and trials were conducted in pseudorandom order. Startle magnitude was calculated based on the pulse-alone (120 dB) trials and the prepulse + pulse trials. Percentage prepulse intensities (%PPI) for the three prepulse intensities were derived using the formula: %PPI = (pulse-alone − prepulse + pulse)/(pulse-alone) × 100%. Possible significant differences were analyzed using Student's \( t \) test. \( P < 0.05 \) was considered significant.

**TUNEL and DAPI Histochemistry**

Four sets of rats injected with GW4869 or vehicle control from the acoustic startle reflex experiment were sacrificed 1 day after experiment, to determine if GW4869 inhibition of nSMase2 led to cell death. Animals were anesthetized deeply and perfused through the left cardiac ventricle with Ringer's solution followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were harvested and sectioned coronally at 20 μm using a cryostat. Sections were mounted on slides coated with gelatin and observed using a microscope to locate the needle track from intrastriatal injections to establish the plane for TUNEL staining. Sections were made permeable with 0.1% Triton X-100 and 0.1% sodium citrate in PBS for 10 min on ice. TUNEL staining was done with In-Situ Cell Death Detection Kit, Fluorescein (Roche Diagnostics, Basel, Switzerland) to identify DNA fragmentation, according to the manufacturer’s protocol. The nuclear counterstaining and mounting agent used was ProLong® Gold Anti-fade reagent with DAPI (Invitrogen, Waltham, USA). Positive controls were incubated with

**Fig. 4** Light micrographs of control and nSMase2-immunolabeled sections of the rat CNS. a Control section from the striatum which had been incubated with PBS instead of primary antibody, showing absence of staining. b Low magnification showing the dorsal striatum (caudate-putamen, CPU) and globus pallidus (GP). White matter tracts such as the corpus callosum (CC) are unlabeled. c Moderately dense staining is found in the olfactory bulb (OB). d Moderately dense staining is found in the prefrontal cortex (PFC). III indicates layer III. e Dense staining is found in the form of puncta in the neuropil, in the caudate-putamen (CPU). f Light labeling is observe in the hippocampus. CA1, field CA1; SP, stratum pyramidale (SP). g Light labeling is found in the thalamus (TH). h Dense labeling is found in the dorsal horn (DH) of the spinal cord. Scale: a, c–h = 200 μm. b = 2 mm
DNase I (3 U/μl) (Roche Diagnostics) for 10 min at room temperature. Sections were examined with an Olympus BX51 microscope (Olympus, Tokyo, Japan).

Results

Differential mRNA Expression of SMase Isoforms in the CNS

The mRNA expression of different sphingomyelinase isoforms was quantified by real-time RT-PCR, to determine their relative expression in the brain. nSMase3, acid sphingomyelinase, and nSMase2 were found to have higher expression than nSMase 1 in the brain (Fig. 1). However, since other studies measuring nSMase activity have raised the possibility that nSMase3 activity may differ from that of other nSMases [34], and nSMase3 does not share any sequence homology or common catalytic core residues with other nSMase isoforms [8], nSMase2 was chosen for further analysis in this study.

Expression of nSMase2 in Different Brain Regions at mRNA, Protein, and Cellular and Subcellular Levels

Comparison of mRNA level of nSMase2 in different regions of the CNS showed that expression was highest in the striatum, followed by the prefrontal cortex, hippocampus, cortex 1 (which includes the primary and secondary motor cortex and primary somatosensory cortex), cortex 2 (which includes the parietal association cortex and secondary auditory cortex), cerebellum, thalamus, brainstem, and olfactory bulb (Fig. 1).

The protein expression of nSMase2 in different brain regions was then determined. Western blotting with nSMase2 antibody detected a single 71-kDa band in the adult rat brain, consistent with the expected molecular weight of full length nSMase2 protein. Antisense knockdown of nSMase2 resulted in reduced density of the 71-kDa band, indicating effectiveness of the knockdown, as well as specificity of the antibody (Fig. 2). The striatum had the highest level of nSMase2 protein expression, followed by the prefrontal cortex, thalamus, hippocampus, brainstem, and cerebellum (Fig. 3a, b).

The cellular distribution of nSMase2 was next elucidated (Fig. 4). Control sections incubated with PBS instead of primary antibody showed absence of immunostaining (Fig. 4a), while parts of the brain were labeled in sections incubated with nSMase2 antibody (Fig. 4b). Dense labeling was observed in the striatum, including the caudate-putamen (Fig. 4b, e), while moderately dense staining was found in the olfactory bulb (Fig. 4c) and cerebral neocortex (Fig. 4d). The hippocampus (Fig. 4f) and thalamus (Fig. 4g) were lightly stained. Dense staining was found in the cochlear nuclei and dorsal horn of the spinal cord (Fig. 4h). The labeling pattern took the form of puncta in the neuropil, and cell outlines were indistinct. White matter tracts were very lightly labeled or unlabeled.

The subcellular localization of nSMase2 was further examined (Fig. 5). Electron microscopy of nSMase2-immunolabeled sections of the caudate-putamen showed that immunoreaction product was present in small diameter dendrites or dendritic spines, that formed asymmetrical synapses with unlabeled axon terminals containing small round vesicles, and characteristics of glutamatergic axons (Fig. 5a, b). The dendrites are putatively identified as those of medium spiny neurons in the caudate-putamen, and the axon terminals, as that of glutamatergic axons from the motor cortex.

Alteration of Striatal Sphingolipids Due to Intrastriatal Inhibition of nSMase

Lipidomic analysis showed significant increases in long chain sphingomyelin species 36:1 and 38:1 after intrastriatal injection of GW4869 indicating effectiveness of the inhibitor (Fig. 6). However, there was an absence of change in their
corresponding ceramides. There was also an absence of change in another sphingomyelin species 34:1 (Fig. 6). Results showed that nSMase inhibition causes accumulation in certain long chain sphingomyelin species, but does not affect total ceramide levels.

**Alteration of Striatal Lipid Raft Proteome after Intrastriatal Inhibition or Knockdown of nSMase2**

A total of 1423 high-confidence proteins were identified by proteomic profiling, with multiple peptides and < 1% FDR. We used a cutoff ratio value of 0.5 for downregulated and ratio value of 2 as upregulated proteins, i.e., 2-fold change. We identified a total of 269 downregulated proteins in lipid rafts of the striatum after nSMase2 antisense injection to the caudate-putamen, while a total of 383 proteins were downregulated after GW4869 injection. The common downregulated proteins in both treatment groups are listed in Table 3. Surprisingly, no common upregulated protein was identified. Results are consistent with the notion that nSMase2 activity is important for the aggregation or clustering of proteins in lipid rafts. A protein, annexin A6, was downregulated by 9-fold and 16-fold in the nSMase2 antisense and inhibitor injection group, respectively. Annexin 6 is present in lipid rafts of synaptic membranes [35]. It regulates plasma membrane remodeling of lipid rafts [36] and acts as a scaffold to link membrane microdomains with the cytoskeleton [37]. Other proteins that showed decreases after nSMase2 inhibition or antisense treatment include hippocalcin, which has been localized to Lewy bodies [38], N-myc downstream-regulated gene 1 (NDRG1), and carbonyl reductase 1.

**Rotarod Test**

Rats injected with GW4869 in the striatum remained on the rotarod for a significantly shorter period of time, as compared to saline-injected controls ($p<0.05$) (Fig. 7a). Likewise, rats injected with antisense nSMase2 oligonucleotide remained on the rotarod for a significantly shorter period of time, as compared to scrambled sense-injected controls ($p<0.05$) (Fig. 8a).
### Table 3
Proteins decreased in lipid raft fractions of rats injected with GW4869 nSMase inhibitor (Inb) or saline (Sal); or antisense (AS) vs. scrambled sense (SS)

| Gene symbol | Name                                               | Pro_Mass | AS/SS   | Inb/Sal   |
|-------------|----------------------------------------------------|----------|---------|-----------|
| Eef2        | Elongation factor 2                                | 96192    | 0.082391| 0.356     |
| Anxa6       | Annexin                                            | 76108    | 0.105078| 0.061913  |
| Prdx5       | Isoform cytoplasmic + peroxisomal of peroxiredoxin-5, mitochondrial | 17195    | 0.115124| 0.252525  |
| Lonp1       | Lon protease homolog, mitochondrial               | 106296   | 0.139431| 0.267     |
| Aars        | Alanine-tRNA ligase, cytoplasmic                   | 107522   | 0.139431| 0.4005    |
| Hpca        | Neuron-specific calcium-binding protein hippocalcin| 22527    | 0.174288| 0.205385  |
| LOC100361259| 60S ribosomal protein L13                         | 24168    | 0.179974| 0.492118  |
| Ctna1       | Catenin (cadherin-associated protein), alpha 1     | 100858   | 0.18126 | 0.4984    |
| Spr         | RCG56371                                           | 28510    | 0.185908| 0.34176   |
| Ssrp1       | FACT complex subunit SSRP1                         | 81206    | 0.185908| 0.438154  |
| Ndrg1       | Protein NDRG                                       | 43383    | 0.193344| 0.167529  |
| Anxa7       | Annexin                                            | 50272    | 0.2014  | 0.237333  |
| Brr1        | Carbonyl reductase [NADPH] 1                       | 30920    | 0.210555| 0.248121  |
| Coro1c      | Coronin                                            | 53828    | 0.220765| 0.328615  |
| Dpp6        | Dipeptidyl aminopeptidase-like protein 6           | 91842    | 0.2226  | 0.412211  |
| Celf2       | CUGBP Elav-like family member 2                    | 54291    | 0.231018| 0.397882  |
| Oxr1        | Oxidation resistance protein 1                     | 97418    | 0.232385| 0.323636  |
| Gng3        | Guanine nucleotide-binding protein subunit gamma   | 8527     | 0.250224| 0.294869  |
| H3f3b       | Histone H3                                         | 15376    | 0.255078| 0.441192  |
| A0A0G2JTG1  | Uncharacterized protein                            | 9382     | 0.256959| 0.286437  |
| Park7       | Park7 protein                                      | 23002    | 0.260142| 0.44144   |
| Tsg101      | Tumor susceptibility gene 101                      | 44221    | 0.264338| 0.3115    |
| Fkbp1a      | Peptidyl-prolyl cis-trans isomerase FKBP1A         | 11972    | 0.270931| 0.462391  |
| Frs11       | DOMON domain-containing protein FRRS1L             | 32892    | 0.271452| 0.314986  |
| Hist1b4b    | Histone H4                                         | 11360    | 0.27173 | 0.416595  |
| Pabpc1      | Polyadenylate-binding protein 1                    | 60149    | 0.27189 | 0.408525  |
| RpL24       | 60S ribosomal protein L24                          | 17779    | 0.273329| 0.196058  |
| Chchd6      | MICOS complex subunit Mic25                       | 29592    | 0.2736  | 0.449684  |
| A0A0G2KBA1  | Uncharacterized protein                            | 31964    | 0.274636| 0.319673  |
| Erp29       | Endoplasmic reticulum resident protein 29          | 28614    | 0.274636| 0.323636  |
| Pitpna      | Phosphatidylinositol transfer protein alpha isoform| 32059    | 0.276925| 0.209412  |
| Actn3       | Actin in alpha 3, isoform CRA_a                     | 103575   | 0.278862| 0.4272    |
| Lac12       | LanC lantibiotic synthetase component C-like 2 (bacterial) | 51677    | 0.278862| 0.4628    |
| Ube2n       | Ubiquitin-conjugating enzyme E2 N                  | 17170    | 0.281023| 0.331163  |
| Ndufs7      | NADH dehydrogenase (ubiquinone) Fe-S protein 7     | 24215    | 0.28186 | 0.212085  |
| Blvrb       | Biliverdin reductase B (flavin reductase (NADPH))  | 22194    | 0.283219| 0.33375   |
| Dyn1l2      | Dynamin light chain 2, cytoplasmic                 | 10457    | 0.283631| 0.366812  |
| Atp5j2      | ATP synthase subunit f, mitochondrial              | 10503    | 0.283934| 0.368729  |
| Rab7a       | Ras-related protein Rab-7a                        | 21361    | 0.284329| 0.440145  |
| Sdhb        | Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial| 32607    | 0.287714| 0.090127  |
| Canx        | Calnexin                                           | 67612    | 0.287714| 0.237333  |
| Pdxp        | Pyridoxal phosphate phosphatase                    | 33380    | 0.287714| 0.339048  |
| Cdc42       | Cell division control protein 42 homolog          | 21696    | 0.292945| 0.146051  |
| Cars         | Cysteinyl-tRNA synthetase (predicted), isoform CRA_b| 86110    | 0.3021  | 0.237333  |
| Cacnb2      | Calcium channel, voltage-dependent, beta 2 subunit, isoform CRA_d| 68596    | 0.3021  | 0.237333  |
| Ppp2r5b     | Protein LOC100909468                               | 57746    | 0.3021  | 0.34176   |
| Lrrc7       | Leucine-rich repeat-containing protein 7           | 168690   | 0.3021  | 0.356     |
| Ddx5        | DEAD (Asp-Glu-Ala-Asp) box polypeptide 5           | 69709    | 0.3021  | 0.356     |
| Gene symbol | Name                                      | Pro_Mass | AS/SS | Inh/Sal |
|------------|-------------------------------------------|----------|-------|---------|
| Atad3      | ATPase family AAA domain-containing protein 3 | 66889    | 0.3021| 0.356   |
| Gad2       | Glutamate decarboxylase 2                 | 66215    | 0.3021| 0.356   |
| Sacm11     | Phosphatidylinositol phosphatase SAC1      | 67509    | 0.3021| 0.356   |
| Clip2      | CAP-Gly domain-containing linker protein 2 | 115975   | 0.3021| 0.356   |
| Aldh2      | Aldehyde dehydrogenase, mitochondrial     | 56994    | 0.314688| 0.303787|
| Uqr10      | Protein Uqr10                             | 7095     | 0.318671| 0.150211|
| Pdia3      | Protein disulfide-isomerase               | 57499    | 0.3192 | 0.322415|
| Suclg1     | Succinate-CoA ligase, GDP-forming, alpha subunit, isoform CRA_b | 37935    | 0.336958| 0.4628  |
| Pascin1    | Protein kinase C and casein kinase substrate in neurons protein 1 | 50760    | 0.344848| 0.277985|
| Atp5o      | ATP synthase subunit O, mitochondrial     | 23440    | 0.355412| 0.418824|
| Btdb8      | Protein Btdb8                             | 149108   | 0.359643| 0.32752 |
| Rpl30      | 60S ribosomal protein L30                | 12947    | 0.359643| 0.32752 |
| Idh3B      | Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial | 42612    | 0.359643| 0.32752 |
| Hnmpab     | CARG-binding factor A                     | 30948    | 0.359643| 0.32752 |
| Ube2o      | Protein Ube2o                             | 126509   | 0.359643| 0.32752 |
| Pcdh1      | Protein Pcdh1                             | 129114   | 0.359643| 0.32752 |
| Fam49a     | Family with sequence similarity 49, member A | 37704    | 0.359643| 0.32752 |
| Cox6c2     | Cytochrome c oxidase subunit 6C-2         | 8449     | 0.359643| 0.32752 |
| Cryab      | Alpha-crystallin B chain                  | 20076    | 0.359643| 0.32752 |
| Hspa5      | 78-kDa glucose-regulated protein          | 72473    | 0.359643| 0.32752 |
| Sfpq       | Protein Sfpq                              | 75210    | 0.359643| 0.32752 |
| Gsta1      | Glutathione S-transferase                 | 25360    | 0.359643| 0.32752 |
| Rac1       | Ras-related C3 botulinum toxin substrate 1 | 24636    | 0.359643| 0.32752 |
| Pip4k2b    | Phosphatidylinositol 5-phosphate 4-kinase type-2 beta | 47633    | 0.359643| 0.32752 |
| Dnm11      | Dynamin-1-like protein                    | 84369    | 0.359643| 0.32752 |
| Ccsap      | Protein Ccsap                            | 28584    | 0.359643| 0.32752 |
| Cct5       | T-complex protein 1 subunit epsilon       | 59955    | 0.359643| 0.32752 |
| Ehd3       | EH domain-containing protein 3            | 60810    | 0.359643| 0.32752 |
| Scrn1      | Secerin-1                                | 46994    | 0.359643| 0.32752 |
| Lynx1      | Ly6/neurotoxin 1 (predicted), isoform CRA_a | 13396    | 0.359643| 0.32752 |
| P11517     | Hemoglobin subunit beta-2                 | 16086    | 0.359643| 0.32752 |
| Map4       | Microtubule-associated protein            | 235075   | 0.359643| 0.32752 |
| Hnmpm      | Isoform 2 of heterogeneous nuclear ribonucleoprotein M | 56864    | 0.359643| 0.32752 |
| Wdr13      | Protein Wdr13                            | 43571    | 0.359643| 0.32752 |
| Epm2       | Epsin 2                                  | 68809    | 0.359643| 0.32752 |
| Atp1a2     | Sodium/potassium-transporting ATPase subunit alpha-2 | 113457   | 0.359643| 0.32752 |
| LOC684681  | Protein LOC684681                        | 21308    | 0.359643| 0.32752 |
| Pabpc4     | Polyadenylate-binding protein             | 71188    | 0.359643| 0.32752 |
| Atp4a      | Sodium/potassium-transporting ATPase subunit alpha | 115674   | 0.359643| 0.32752 |
| Mog        | Myelin-oligodendrocyte glycoprotein      | 28153    | 0.359643| 0.32752 |
| Nono       | Non-POU domain-containing octamer-binding protein | 55005    | 0.359643| 0.32752 |
| Phb2       | Prohibitin-2                             | 33148    | 0.359643| 0.32752 |
| Rhob       | Rho-related GTP-binding protein Rhob      | 22565    | 0.359643| 0.32752 |
| Ldha       | L-lactate dehydrogenase                   | 36712    | 0.359643| 0.32752 |
| Syncr1     | Heterogeneous nuclear ribonucleoprotein Q | 62861    | 0.359643| 0.32752 |
| Rtn4r2     | Reticulon-4 receptor-like 2               | 46896    | 0.359643| 0.32752 |
| Gstm3      | Glutathione S-transferase Yb-3            | 25835    | 0.359643| 0.32752 |
| Atp6v1c1   | V-type proton ATPase subunit C 1          | 44044    | 0.359643| 0.32752 |
| Palm       | Paralemmin-1                             | 42072    | 0.359643| 0.32752 |
Beam Crossing Test

Rats exhibited poorer performance on the beam crossing test after intrastriatal injection of GW4869. These were unable to place both hind paws on the horizontal surface of the beam but attempted to balance and traverse the beam by placing their forepaw on the horizontal surface and dragging themselves across the beam, before losing balance and falling off the beam. They were unable to successfully cross the beam in all except one trial (Fig. 7b). Rats injected with vehicle control showed no significant difference in performance before and after injection. There was no significant difference in time taken to cross the beam, between the two groups, before injection. Rats injected with antisense oligonucleotides to nSMase2 showed significantly poorer performance in the balance beam test, compared to scrambled sense-injected controls ($p < 0.05$) (Fig. 8b).

Acoustic Startle Reflex Test and Prepulse Inhibition of Acoustic Startle

The amplitude of the acoustic startle response was first compared using pulse-alone trials. Rats that received GW4869 injection showed significantly decreased acoustic startle response compared to saline-injected controls (Fig. 9a). Prepulse inhibition (PPI) of the auditory startle response was also determined after GW4869 or saline injection. Rats that received GW4869 injection showed significantly increased PPI as compared to saline-injected controls (Fig. 9b).

TUNEL and DAPI Histochemistry

GW4869 treatment did not cause an increase in nuclear fragmentation in the TUNEL assay, while positive control sections displayed TUNEL-positive staining of the nuclei. Results imply that injected treatments did not cause the induction of cell death in the striatum (Supplementary Figure).

Discussion

nSMase2 is the most well-studied mammalian nSMase of the sphingomyelinase family and has been shown to be mainly found in the brain [7, 39, 40]. Our real-time RT-PCR results showed that nSMase2 mRNA is present in different brain regions, with the highest expression in the striatum, followed by the cerebral cortex and low expression in the brainstem and cerebellum. Western blots showed high levels of nSMase2 protein expression in the striatum and cortex and low expression in the brainstem and cerebellum, which is consistent with the RT-PCR results. The 71-kDa band detected is in accordance with the molecular weight of full length nSMase2 [4] and was significantly reduced by antisense oligonucleotide knockdown in the striatum, indicating specificity of the antibody. Immunohistochemical analyses revealed dense staining in the striatum, cochlear nuclei, and dorsal horn of the spinal cord, and moderate staining in cerebral neocortex. White matter tracts such as the corpus callosum were very lightly labeled or unlabeled. The above results are in agreement with previous findings that nSMase activity is highest in the striatum among different regions in the human and rat brain—with activity in the stratum being 2.7 times greater than that of the parietal cortex, and 10 times that of the cerebellum, brainstem, and corpus callosum [28, 39]. Although our real-time RT-PCR results reveal high nSMase3 expression across all brain regions including the brainstem and cerebellum, previous studies that measured nSMase enzymatic activity have failed to detect this trend [28]. nSMase3 does not share any sequence homology or catalytic core residues [8] and its activity may differ from other nSMases [34]. It is possible that nSMase3 may have a different function from other isoforms in the brain.

Lipidomic analysis showed that SM36:1 and SM38:1 were increased after nSMase was blocked in the striatum, indicating effectiveness of the GW4869 nSMase inhibitor. However, there was an absence of change in another sphingomyelin species.
34:1, consistent with previous reports that nSMase2 exhibits substrate preference for longer chain sphingomyelins [41]. Interestingly, an expected decrease in corresponding 36:1 and 38:1 ceramides was not observed. Results indicate that nSMase inhibition causes accumulation in certain sphingomyelin species by preventing breakdown into their corresponding ceramides. The unchanged ceramide levels after nSMase inhibition may be due to compensation from de novo sphingolipid synthesis, which is a major source of ceramide generation and the only source of non-dietary sphingolipids [42]. These findings suggest that sphingomyelin accumulation is the primary cause of the observed phenotype, and not the depletion of ceramides per se. Proteomic analyses showed significant decreases in many proteins due to inhibition or antisense knockdown of nSMase2 in the striatum. This could have functional consequences due to changes in aggregation or clustering of these proteins. One of the proteins that showed decreases after antisense knockdown or inhibition of nSMase2 is annexin A6. This is a member of the annexin family of calcium-dependent membrane and phospholipid-binding proteins, which creates a scaffold for the formation of multifactorial signaling complexes and functions as an organizer of membrane domains to modulate intracellular
cholesterol homeostasis, and regulates transient membrane-actin interactions during endocytic and exocytic transport \[37, 43\].

The high level of expression of nSMase2 in the striatum suggests that the enzyme may be important in the function of this brain region. We investigated the involvement of nSMase2 in motor function and coordination via intrastriatal injection of GW4869 a well-established specific inhibitor of nSMase2 that does not affect A-SMase activity \[12, 23, 44–49\], or antisense oligonucleotide to nSMase2. Rats that received intrastratal injection of GW4869 or antisense oligonucleotide to nSMase2 showed impaired motor function in the rotarod test, and remained on the rotarod for a shorter duration compared to controls. Similarly, rats injected with GW4869 or antisense oligonucleotide displayed poorer motor coordination in the beam crossing test, with all rats falling off the beam and unable to successfully cross the beam. Results indicate an important role of nSMase2 in regulation of motor activity and coordination \[50\]. A role of nSMase2 in the startle reflex and prepulse inhibition of startle was also investigated. Inhibition of nSMase2 in the striatum resulted in decreased acoustic startle response and increased prepulse inhibition (%PPI) compared to controls, indicating an improvement in sensorimotor gating. Besides the caudate-putamen or dorsal striatum, it is possible that nSMase2 could have a role in the ventral striatum and the reward pathway, which extends from the ventral tegmental area to the nucleus accumbens shell \[51\]. This possibility needs to be investigated in future studies.

The exact molecular mechanisms of how nSMase2 plays a role in the regulation of striatal activity are not fully understood. Nevertheless, our EM finding that nSMase2 was present in small diameter dendrites or dendritic spines of asymmetrical synapses with unlabeled axon terminals that contained small round vesicles, and features of glutamatergic axons \[52, 53\], suggests that it may affect excitatory neurotransmission. Lipid rafts are docking sites for glutamate receptors \[54–56\], and nSMase2 has been shown to regulate AMPA receptor numbers and NMDA glutamate receptor subunit composition and clustering \[22, 23\]. Long-term inhibition of nSMase2 increases PSD-95, as well as the amount of NMDA receptor NR2A subunits and AMPA receptor GluR1 subunits \[23\]. Knockout of the AMPA receptor subunit GluR1 results in increased level of dopamine in the striatum \[57\] and increased locomotion \[58\]. We postulate that nSMase2 could have a role in modulating glutamatergic transmission, and that enzyme inhibition could result in alterations in excitatory transmission at the corticostratal synapse and decreased motor function. A change in excitatory transmission could also be consistent with the observed improvement in prepulse inhibition of the auditory startle response. Further work is necessary to determine the molecular mechanisms of nSMase2 action in the brain, and possible changes in enzyme activity in neurological and psychiatric disorders.

**Funding information** This work was supported by grants from the National Medical Research Council and the National University Health System of Singapore.

**Compliance with Ethical Standards** All procedures were in accordance with the Principles of Laboratory Animal Care and approved by the Institutional Animal Care and Use Committee of the National University of Singapore.
Conflict of Interest  The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bielawska A, Linardic CM, Hannun YA (1992) Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acetyl-phenylalaninolacohol analogs. J Biol Chem 267(26):18493–18497
2. Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva M, Obeid LM, Hannun YA (1995) Role for ceramide in cell cycle arrest. J Biol Chem 270(5):2047–2052
3. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S (1994) Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci U S A 91(1):73–77
4. Clarke CJ, Snook CF, Tani M, Matmati N, Marchesini N, Hannun YA (2006) The extended family of neutral sphingomyelinas. Biochemistry 45(38):11247–11256. https://doi.org/10.1021/bi061307z
5. Jenkins RW, Canals D, Hannun YA (2009)Roles and regulation of secretory and lysosomal acid sphingomyelinas. Cell Signal 21(6):836–846
6. Shamseddine AA, Airola MV, Hannun YA (2015) Roles and regulation of neutral sphingomyelinas-2 in cellular and pathological processes. Adv Biol Regul 57:24–41. https://doi.org/10.1016/j.bior.2014.10.002
7. Hofmann K, Toniuk S, Wolff G, Stoffel W (2000)Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinas. Proc Natl Acad Sci U S A 97(11):5895–5900
8. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M (2006) Novel tumor necrosis factor-response mammalian neutral sphingomyelinas-3 is a C-tail-anchored protein. J Biol Chem 281(19):13784–13793. https://doi.org/10.1074/jbc.M511306200
9. Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J (2005) Amyloid-beta peptide enhances tumor necrosis factor-alpha induced iNOS through neutral sphingomyelinas/ceramide pathway in oligodendrocytes. J Neurochem 94(3):703–712. https://doi.org/10.1111/j.1471-4159.2005.02312.x
10. De Palma C, Meacci C, Perrotta C, Bruni P, Clementi E (2006) Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinas, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol 26(1):99–105. https://doi.org/10.1161/01.ATV.0000194074.59584.42
11. Wascholovsky V, Giannis A, Pitsinos EN (2006) Influence of the sphyrophastatin side chain on the mode of inhibition of neutral sphingomyelinas. ChemMedChem 1(7):718–721. https://doi.org/10.1002/cmdc.200600099
12. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM et al (2002) Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinas. J Biol Chem 277(43):41128–41139. https://doi.org/10.1074/jbc.M206747200
13. Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, BandaruVV, Yoo SW, Westwood NJ, Rogers GW et al (2015) Cambinol, a novel inhibitor of neutral sphingomyelinas 2 shows neuroprotective properties. PLoS One 10(5):e0124481. https://doi.org/10.1371/journal.pone.0124481
14. Sawai H, Domae N, Nagan N, Hannun YA (1999) Function of the cloned putative neutral sphingomyelinas as lyso-platelet activating factor-phospholipase C. J Biol Chem 274(33):38131–38139
15. Lennarz WJ, Lane MD (2013) Encyclopedia of Biological Chemistry. Elsevier Science. Amsterdam, The Netherlands
16. Wu BX, Clarke CJ, Hannun YA (2010) Mammalian neutral sphingomyelinas: regulation and roles in cell signaling responses. NeuroMolecular Med 12(4):320–330. https://doi.org/10.1007/s12017-010-8120-z
17. Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA (2004) Role for mammalian neutral sphingomyelinas 2 in confluenence-induced growth arrest of MCF7 cells. J Biol Chem 279(24):25101–25111. https://doi.org/10.1074/jbc.M313662200
18. Karakashian AA, Giltiay NV, Smith GM, Nikolova-Karakashian MN (2004) Expression of neutral sphingomyelinas-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18(9):968–970. https://doi.org/10.1096/fj.03-0875fje
19. Clarke CJ, Guthrie JM, Hannun YA (2008) Regulation of neutral sphingomyelinas-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells. Mol Pharmacol 74(4):1022–1032. https://doi.org/10.1124/mol.107.046250
20. Franco-Villanueva A, Fernandez-Lopez E, Gabande-Rodriguez E, Banon-Rodriguez I, Esteban JA, Antom IM, Ledeema MD (2014) WIP modules dendritic spine actin cytoskeleton by transcriptional control of lipid metabolic enzymes. Hum Mol Genet 23(16):4383–4395. https://doi.org/10.1093/hmg/ddu155
21. Brann AB, Scott R, Neuberger Y, Abulafia D, Boldin S, Fainzilber M, Futerman AH (1999) Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. The Journal of Neuroscience : the official journal of the Society for Neuroscience 19(19):8199–8206
22. Wheeler D, Knapp E, Bandaru VVR, Wang Y, Knorr D, Poirier C, Mattson MP, Geiger JD et al (2009) TNF-alpha neutral sphingomyelinas-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem 109(5):1237–1249. https://doi.org/10.1111/j.1471-4259.2009.06038.x
23. Tabatzadze N, Savonenko A, Song H, Bandaru VV, Chua M, Haughey NJ (2010) Inhibition of neutral sphingomyelinas-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res 88(13):2940–2951. https://doi.org/10.1002/jnr.22438
24. Kim SK, Ahn KH, Ji JE, Choi JM, Jeon HY, Jung SY, Jung KM, Kim DK (2010) Neutral sphingomyelinas 2 induces dopamine uptake through regulation of intracellular calcium. Cell Signal 22(5):865–870. https://doi.org/10.1016/j.cellsig.2010.01.012
25. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DJ, Chen S, Hsu CY (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinas/ceramide pathway. J Cell Biol 164(1):123–131. https://doi.org/10.1083/jcb.200307017
26. Ju TC, Chen SD, Liu CC, Yang DJ (2005) Protective effects of S-nitrosogluthatine against amyloid beta-peptide neurotoxicity. Free Radic Biol Med 38(7):938–949. https://doi.org/10.1016/j.freeradbiomed.2004.12.019
27. Ong WY, Herr DR, Farooqui T, Ling EA, Farooqui AA (2015) Role of sphingomyelinas in neurological disorders. Expert Opin Ther Targets 19(12):1725–1742. https://doi.org/10.1517/14728222.2015.1071794
28. Sperker ER, Spence MW (1983) Neutral and acid sphingomyelinas of rat brain: somatotopographical distribution and activity following experimental manipulation of the dopaminergic system in vivo. J Neurochem 40(4):1182–1184
29. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San Diego
30. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262
31. Alshery ZH, Barlow CK, Weir JM, Zhou Y, McConville MJ, Meikle PJ (2015) An efficient single phase method for the extraction of plasma lipids. Meta 5(2):389–403. https://doi.org/10.3390/metabo5020389
32. Taruno A, Sun H, Nakajo K, Murakami T, Ohsaki Y, Kido MA, Ono F, Marunaka Y (2017) Post-translational palmitoylation controls the voltage gating and lipid raft association of the CALHM1 channel. J Physiol. https://doi.org/10.1113/JP274164
33. Powell SB, Swerdlow NR, Pitcher LK, Geyer MA (2002) Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiol Behav 77(1):55–64. https://doi.org/10.1016/S0031-9384(02)00817-X
34. Clarke CJ, Cloessner EA, Roddy PL, Hannun YA (2011) Neutral sphingomyelinas 2 (nSMase2) is the primary neutral sphingomyelinas isoform activated by tumour necrosis factor-alpha in MCF-7 cells. The Biochemical journal 435(2):381–390. https://doi.org/10.1042/BJ20101752
35. Orito A, Kumanogoh H, Yasaka K, Sokawa J, Hidaka H, Sokawa Y, Mackawa S (2001) Calcium-dependent association of annexin VI, protein kinase C alpha, and neurocalcin alpha in MCF-7 cells. The Biochemical journal 435(2):381–390. https://doi.org/10.1042/BJ20101752
36. Clarke CJ, Cloessner EA, Roddy PL, Hannun YA (2011) Neutral sphingomyelinas 2 (nSMase2) is the primary neutral sphingomyelinas isoform activated by tumour necrosis factor-alpha in MCF-7 cells. The Biochemical journal 435(2):381–390. https://doi.org/10.1042/BJ20101752
37. Ayer L, Spence MW (1987) Magnesium-dependent sphingomyelinase. Biochem J 241:253–241. https://doi.org/10.1042/ijt1071
38. Alvarez-Guaita A, Vila de Muga S, Owen DM, Williamson D, Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinas: roles and mechanisms of regulation. Biochem Cell Biol 82(1):27–44. https://doi.org/10.1139/o03-091
39. Smith AR, Visioli F, Frei B, Hagen TM (2006) Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinas and ceramide-activated phosphatase 2A. Aging Cell 5(5):391–400. https://doi.org/10.1111/j.1471-4942.2006.00232.x
40. Seidler RD, Bernard JA, Burutolu TB, Fling BW, Gordon MT, Gwin JT, Kwak Y, Lisps DB (2010) Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev 34(5):721–733. https://doi.org/10.1016/j.neubiorev.2009.10.005
41. Carlezen WA Jr, Thomas MJ (2009) Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropsycharmacology 56(Suppl 1):122–132. https://doi.org/10.1016/j.neuropharm.2008.06.075
42. Gray EG (1959) Axo-somatic and axo-dendritic synapses of the cerebral cortex: an electron microscope study. J Anat 93:420–433
43. Klemann CJ, Roubos EW (2011) The gray area between synapse types, dendritic spines, and surface AMPA receptor stability. J Neurosci Biobehav Rev 34(5):721–733. https://doi.org/10.1016/j.neubiorev.2009.10.005
44. Canals D, Perry DM, Jenkins RW, Hannun YA (2011) Drug targeting of sphingolipid metabolism: sphingomyelinas and ceramidades. Br J Pharmacol 163(4):694–712. https://doi.org/10.1111/j.1476-5318.2011.01279.x
45. Airola MV, Hannun YA (2013) Sphingolipid metabolism and neural sphingomyelinas. Handb Exp Pharmacol 215:57–76. https://doi.org/10.1007/978-3-7091-1368-4_3
46. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A et al (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55(2):257–267. https://doi.org/10.1002/ana.10828
47. Kolmakova A, Kwiertovich P, Virgil D, Alapovic P, Knight-Gibson C, Martin SF, Chatterjee S (2004) Apolipoprotein C-1 induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinas. Arterioscler Thromb Vasc Biol 24(2):264–269. https://doi.org/10.1161/01.ATV.0000112036.72200.ac
48. Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinas: roles and mechanisms of regulation. Biochem Cell Biol 82(1):27–44. https://doi.org/10.1139/o03-091
49. Smith AR, Visioli F, Frei B, Hagen TM (2006) Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinas and ceramide-activated phosphatase 2A. Aging Cell 5(5):391–400. https://doi.org/10.1111/j.1471-4942.2006.00232.x
50. Seidler RD, Bernard JA, Burutolu TB, Fling BW, Gordon MT, Gwin JT, Kwak Y, Lisps DB (2010) Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev 34(5):721–733. https://doi.org/10.1016/j.neubiorev.2009.10.005
51. Carlezen WA Jr, Thomas MJ (2009) Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropsycharmacology 56(Suppl 1):122–132. https://doi.org/10.1016/j.neuropharm.2008.06.075
52. Gray EG (1959) Axo-somatic and axo-dendritic synapses of the cerebral cortex: an electron microscope study. J Anat 93:420–433
53. Klemann CJ, Roubos EW (2011) The gray area between synapse structure and function-Gray’s synapse types I and II revisited. Synapse 65(11):1222–1230. https://doi.org/10.1002/syn.20962
54. Bessho S, Bawa D, Teves L, Wallace MC, Gurd JW (2005) Increased phosphorylation and redistribution of NMDA receptors between synaptic lipid rafts and post-synaptic densities following transient global ischemia in the rat brain. J Neurochem 93(1):186–194. https://doi.org/10.1111/j.1471-4159.2004.03099.x
55. Hou Q, Huang Y, Amato S, Snyder SH, Huganir RL, Man HY (2008) Regulation of AMPA receptor localization in lipid rafts. Mol Cell Neurosci 38(2):213–223. https://doi.org/10.1016/j.mcn.2008.02.010
56. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. The Journal of neuroscience : the official journal of the Society for Neuroscience 23(8):3262–3271
57. Sakai K, Akiyama K, Kashihara K, Tsuchida K, Ujike H, Kuroda S, Shohmori T (1997) AMPA receptors modulate dopamine release in the striatum, as measured by brain microdialysis. Neurochem Int 30(3):329–336
58. Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hehner K, Sprenger R, Celikel T et al (2008) Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors. Mol Psychiatry 13(6):631–640. https://doi.org/10.1038/sj.mp.4002056